Ignite Creation Date:
2025-12-24 @ 5:03 PM
Ignite Modification Date:
2026-02-20 @ 11:40 AM
Study NCT ID:
NCT05564650
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-08
First Post:
2022-08-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Sponsor:
Thomas Jefferson University
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Myelodysplastic Syndrome | View |
| None | MDS | View |
| None | high risk MDS | View |
| None | HR-MDS | View |
| None | Relapsed or Refractory | View |
| None | R/R | View |
| None | relapsed or refractory higher-risk myelodysplastic syndrome | View |
| None | acute myeloid leukemia | View |
| None | AML | View |
| None | bone marrow mononuclear cells | View |
| None | BMMC | View |
| None | Navitoclax | View |
| None | Venetoclax | View |
| None | Decitabine | View |
| None | R/R MDS | View |
| None | BCL-2 | View |
| None | BCL-XL | View |
| None | MCL-1 | View |
| None | BCL-2 family | View |
| None | triplet therapy | View |
| None | dose escalation | View |
| None | dose expansion | View |
| None | Bayesian Optimal Interval (BOIN) | View |
| None | quality of life | View |
| None | PROMIS-Fatigue | View |
| None | EORTC QLQ-C30 | View |